SCHEMBL1573540

SCHEMBL1573540

Cc1nc2ccccc2n1C1CC2COCC(C1)N2

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 10/20 0.44
KCNH2 Q12809 2/20 0.44
CYP2D6 P10635 1/20 0.44
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
OGFRL1 Q5TC84 2/20 0.39
OPRM1 P35372 1/20 0.39
OPRK1 P41145 1/20 0.39
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
PIK3CG P48736 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
CYP11B2 P19099 1/20 0.39
MAPK1 P28482 1/20 0.38
KDR P35968 1/20 0.38
UBE2N P61088 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1573991 1.00 CCR5 (0.44) CCR5KCNH2CYP2D6LMNASMN1; SMN2
SCHEMBL13720260 0.87 CCR5 (0.49) CCR5KCNH2CYP2D6LMNASMN1; SMN2
SCHEMBL4022749 0.87 CCR5 (0.49) CCR5KCNH2CYP2D6LMNASMN1; SMN2
SCHEMBL3863093 0.87 CCR5 (0.49) CCR5KCNH2CYP2D6LMNASMN1; SMN2
SCHEMBL988877 0.87 CCR5 (0.49) CCR5KCNH2CYP2D6LMNASMN1; SMN2
SCHEMBL4028493 0.87 CCR5 (0.49) CCR5KCNH2CYP2D6LMNASMN1; SMN2
Hydrochloric Acid SCHEMBL3525571 0.86 CCR5 (0.48) CCR5KCNH2CYP2D6LMNASMN1; SMN2
Hydrochloric Acid SCHEMBL4160408 0.86 CCR5 (0.48) CCR5KCNH2CYP2D6LMNASMN1; SMN2
Hydrochloric Acid SCHEMBL1573806 0.86 CCR5 (0.48) CCR5KCNH2CYP2D6LMNASMN1; SMN2
SCHEMBL1573774 0.84 CCR5 (0.44) CCR5KCNH2CYP2D6LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1140085-B1 AZABICYCLOALKANES AS CCR5 MODULATORS PHIVCO UK LTD (GB) 2011-04-13 EP disclosed
US-6586430-B1 Administering azabicyclo compounds to treat human immunodeficiency virus infections and respiratory system disorders PFIZER INC. 2003-07-01 US disclosed
US-6531484-B2 Viricides for preventing infection by HIV, treating infection by HIV, delaying of the onset of AIDS, or treating AIDS MERCK & CO., INC. 2003-03-11 US disclosed
US-20020198178-A1 Pyrrolidine modulators of CCR5 chemokine receptor activity MERCK SHARP & DOHME CORP. 2002-12-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198178-A1 Pyrrolidine modulators of CCR5 chemokine receptor activity CCR5, CCR1, CCL5 CCR5 1/4885KCNH2 1793/4885CYP2D6 3550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.